. 2018 Jul 1;17:1533033818783450. doi: 10.1177/1533033818783450

Table 6.

Prognostic Factors of 2-Year Progression-Free Survival; Univariate Analysis and Multivariate Analysis.

Prognostic Factor		All Patients (n = 150)				SBRT Alone (n = 28)				SBRT + TACE (n = 122)
Prognostic Factor		Number	2-Year OS (%)	UVA, P Value	MVA, P Value	Number	2-Year OS (%)	UVA, P Value	MVA, P Value	Number	2-Year OS (%)	UVA, P Value	MVA, P Value
Age, years	≧75	73	35.9	.1027	−	16	63.6	.9466	−	57	30.7	.0643	−
Age, years	<75	77	51.1	.1027	−	12	39.3	.9466	−	65	52.4	.0643	−
Gender	Male	99	42	.825	−	17	24.5	.1219	−	82	44.1	.5285	−
Gender	Female	51	47.5	.825	−	11	80.8	.1219	−	40	39.9	.5285	−
Performance status	0	128	40.9	.1242	−	21	40.1	.0826	−	107	40.9	.5434	−
Performance status	1 or 2	22	68.7	.1242	−	7	100	.0826	−	15	57	.5434	−
CTP class	A	127	46.6	.0936	−	23	52.3	.8956	−	104	45.3	.0484	.028
CTP class	B	23	31.9	.0936	−	5	37.5	.8956	−	18	29.3	.0484	.028
Viral infection	HCV	109	39.7	.0025	.0017	18	58.2	.8181	−	91	36.7	.0017	.001
Viral infection	Non-HCV	41	56.3	.0025	.0017	10	38.6	.8181	−	31	62.4	.0017	.001
BCLC stage	0	80	48.8	.2006	−	17	40.1	.4716	−	63	50	.0946	−
BCLC stage	A	70	38.8	.2006	−	11	62.3	.4716	−	59	35	.0946	−
T stage	T1	113	52.3	.001	.0203	24	50.9	.6021	−	89	52.3	<.0001	.012
T stage	T2	37	18.3	.001	.0203	4	50	.6021	−	33	13.5	<.0001	.012
Greatest tumor dimensions	≧20 mm	63	42.5	.8397	−	12	49.1	.972	−	47	38.6	.8236	−
Greatest tumor dimensions	<20 mm	87	45.4	.8397	−	12	43	.972	−	75	45.4	.8236	−
Tumor location	Central	13	49.4	.32	−	4	33.3	.4061	−	9	40.6	.1224	−
Tumor location	Periferal	137	43.5	.32	−	24	61.9	.4061	−	113	77.8	.1224	−
Diagnosis history	Initial	36	62	.0194	.0153	13	72.9	.0396	−	23	56.6	.1365	−
Diagnosis history	Recurrence	114	38.7	.0194	.0153	15	28.4	.0396	−	99	39.6	.1365	−
Previous treatment (surgery)	Yes	61	37.7	.0891	−	9	31.1	.0773	−	52	38.8	.256	−
Previous treatment (surgery)	No	89	48.9	.0891	−	19	59	.0773	−	70	46.1	.256	−
Previous treatment (RFA/PEI)	Yes	41	37.5	.1796	−	5	33.3	.2962	−	35	38.1	.2956	−
Previous treatment (RFA/PEI)	No	109	46.6	.1796	−	23	54.4	.2962	−	87	44.6	.2956	−
Adverse effects	<Grade 3	122	46.4	.6421	−	23	48.8	.43	−	99	45.6	.3302	−
Adverse effects	≧Grade 3	28	34.8	.6421	−	5	53.3	.43	−	23	30.4	.3302	−
Combination with TACE	Yes	28	49	.1889	−
Combination with TACE	No	122	42.9	.1889	−

Abbreviations: BCLC; Barcelona Clinic Liver Cancer; CTP; Child-Turcotte-Pugh; HCV; hepatitis C virus; MVA, multivariate analyses; OS, overall survival; PFS, progression-free survival; RFA/PEI; radiofrequency ablation/percutaneous ethanol injection; SBRT, stereotactic body radiotherapy; TACE, transcatheter arterial chemoembolization; UVA, univariate analyses.